✦ LIBER ✦

PEDF: a potential molecular therapeutic target with multiple anti-cancer activities

✍ Scribed by Eugene T.H. Ek; Crispin R. Dass; Peter F.M. Choong

Book ID: 116758053
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 208 KB
Volume: 12
Category: Article
ISSN: 1471-4914
DOI: 10.1016/j.molmed.2006.08.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Telomerase: A potential molecular marker

Telomerase: A potential molecular marker and therapeutic target for cancer

✍ Joe Y. Chang 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB

TRAF6 Activation in Multiple Myeloma: A

TRAF6 Activation in Multiple Myeloma: A Potential Therapeutic Target

✍ Hong Liu; Samantha Tamashiro; Stavroula Baritaki; Manuel Penichet; Youhua Yu; Ha 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 518 KB

Geldanamycin as a Potential Anti-Cancer

Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity

✍ Len Neckers; Theodor W. Schulte; Edward Mimnaugh 📂 Article 📅 1999 🏛 Springer US 🌐 English ⚖ 171 KB

Activated mammalian target of rapamycin

Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer

✍ Da-zhi Xu; Qi-rong Geng; Ying Tian; Mu-yan Cai; Xin-juan Fang; You-qing Zhan; Zh 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 736 KB

Concanavalin A: A potential anti-neoplas

Concanavalin A: A potential anti-neoplastic agent targeting apoptosis, autophagy and anti-angiogenesis for cancer therapeutics

✍ Wen-wen Li; Jia-ying Yu; Huai-long Xu; Jin-ku Bao 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 755 KB

Wnt/β-catenin-pathway as a molecular tar

Wnt/β-catenin-pathway as a molecular target for future anti-cancer therapeutics

✍ Susanne Dihlmann; Magnus von Knebel Doeberitz 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 213 KB

Conventional chemotherapeutic drugs used for the treatment of cancer patients in advanced stages have yielded only limited benefit, regarding survival time not to mention cure of the patients. To improve the clinical outcome of cancer, agents aimed at novel molecular targets are required. Colorectal